Ubs Asset Management Americas Inc Uro Gen Pharma Ltd. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 1,377,156 shares of URGN stock, worth $13.9 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,377,156
Previous 1,341,072
2.69%
Holding current value
$13.9 Million
Previous $17 Million
13.89%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding URGN
# of Institutions
137Shares Held
36.2MCall Options Held
57.7KPut Options Held
9.8K-
Rtw Investments, LP New York, NY3.83MShares$38.7 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$29.5 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$23.2 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$22.1 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$17.6 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $229M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...